Re: yep, Alnylam has scrapped ALN-HBV
And I am talking about HBV because that is what the target is not a theoretical model of RNAi.
It is not going to make one jot of difference if ABUS, ARWR, Arcturus or whatever sort RNAi for HepBsAg reduction if ABUS, Spring Bank, Jannsen, Replicor, Gilead or one of several other companies finds a cure to HepB cure via HepBsAg or any other molecular or immune modification first.
If so ARWR can be in the lead for a redundant RNAi therapy if you like.
A little pragmatism would serve well here.
Are you still holding so much ARWR or have you TriMMEd?